Skip to Content
Merck
  • The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects.

The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects.

Blood (2014-01-21)
Giuseppe Colucci, Monika Stutz, Sophie Rochat, Tiziana Conte, Marko Pavicic, Marianne Reusser, Evelyne Giabbani, Anh Huynh, Charles Thürlemann, Peter Keller, Lorenzo Alberio
ABSTRACT

1-deamino-8-d-arginine vasopressin (desmopressin [DDAVP]) is clinically efficacious in patients with mild platelet function disorders but it is not known which mechanisms mediate this effect. Our aim was to evaluate the impact of in vivo DDAVP administration in these patients. We assessed von Willebrand factor (VWF), factor VIII, platelet activation and aggregation, platelet-dependent thrombin generation, and platelet intracellular Na(+)/Ca(2+) fluxes, before and 2 and 4 hours after DDAVP (0.3 µg/kg). We found (1) no significant changes for P-selectin expression, PAC-1 binding, δ-granule content and secretion, and platelet-aggregation; (2) significant decreases of secretion of α-granules and GPIIb-IIIa activation induced by adenosine 5'-diphosphate, convulxin, and thrombin; (3) significant increases of procoagulant platelets induced by convulxin/thrombin and platelet-dependent thrombin generation; and (4) significant increases of intracellular Na(+)/Ca(2+) concentrations. We show that in vivo DDAVP selectively and markedly enhances the ability to form procoagulant platelets and increases platelet-dependent thrombin generation by enhancing Na(+)/Ca(2+) mobilization. This report indicates that the beneficial hemostatic effect of DDAVP is not limited to an increase in large VWF multimers. An enhancement of platelet procoagulant activity appears to be an additional and (at least in platelet disorders) -possibly clinically relevant mechanism of DDAVP's action.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Thrombin from bovine plasma, lyophilized powder, 600-2,000 NIH units/mg protein (biuret)
Sigma-Aldrich
Thrombin from bovine plasma, lyophilized powder, ≥2,000 NIH units/mg protein (E1%/280 = 19.5)
Sigma-Aldrich
Thrombin from bovine plasma, lyophilized powder, 40-300 NIH units/mg protein (biuret)
Sigma-Aldrich
Thrombin from bovine plasma, ≥60 NIH units/mg protein (biuret)
Sigma-Aldrich
Thrombin human, BioUltra, recombinant, expressed in HEK 293 cells, aqueous solution, ≥95% (SDS-PAGE)
Sigma-Aldrich
Thrombin from human plasma, 400-1000 NIH units/mg protein
Sigma-Aldrich
Thrombin from human plasma, lyophilized powder, ≥2800 NIH units/mg protein (E1%/280, 18.3)
Sigma-Aldrich
Thrombin from human plasma, lyophilized powder, 1500-3500 NIH units/mg protein (E1%/280, 18.3), suitable for cell culture
Sigma-Aldrich
Thrombin from human plasma, lyophilized powder, ≥1,000 NIH units/mg protein (E1%/280, 18.3)
Sigma-Aldrich
Thrombin from human plasma, lyophilized powder, Suitable for routine use in the thrombin time test
Sigma-Aldrich
Thrombin from human plasma, lyophilized powder, ≥2,000 NIH units/mg protein (E1%/280, 18.3)